Repligen (RGEN) Rating Increased to Strong-Buy at ValuEngine

ValuEngine upgraded shares of Repligen (NASDAQ:RGEN) from a buy rating to a strong-buy rating in a report published on Tuesday.

A number of other equities analysts have also recently issued reports on RGEN. Stephens upped their target price on Repligen from $50.00 to $55.00 and gave the stock an average rating in a report on Tuesday, July 10th. Citigroup upped their target price on Repligen from $45.00 to $56.00 and gave the stock a buy rating in a report on Friday, July 20th. BidaskClub cut Repligen from a strong-buy rating to a buy rating in a report on Tuesday, July 31st. Zacks Investment Research cut Repligen from a hold rating to a sell rating in a report on Tuesday, August 7th. Finally, JPMorgan Chase & Co. upped their target price on Repligen to $60.00 and gave the stock an overweight rating in a report on Monday, September 24th. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and two have issued a strong buy rating to the stock. The company presently has an average rating of Buy and an average target price of $53.83.

Shares of Repligen stock traded up $1.36 during trading on Tuesday, reaching $54.70. 5,346 shares of the company’s stock were exchanged, compared to its average volume of 313,117. Repligen has a 1-year low of $29.56 and a 1-year high of $58.99. The stock has a market capitalization of $2.46 billion, a P/E ratio of 78.68, a price-to-earnings-growth ratio of 4.51 and a beta of 0.69.



Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). Repligen had a return on equity of 5.05% and a net margin of 13.49%. The business had revenue of $47.73 million for the quarter, compared to analyst estimates of $45.84 million. During the same period last year, the firm posted $0.20 EPS. Repligen’s quarterly revenue was up 47.0% on a year-over-year basis. As a group, research analysts anticipate that Repligen will post 0.71 earnings per share for the current year.

In other Repligen news, CEO Anthony Hunt sold 27,566 shares of the company’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $57.71, for a total value of $1,590,833.86. Following the sale, the chief executive officer now owns 255,017 shares in the company, valued at approximately $14,717,031.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Thomas F. Ryan, Jr. sold 2,366 shares of the company’s stock in a transaction dated Wednesday, August 22nd. The shares were sold at an average price of $51.44, for a total value of $121,707.04. Following the completion of the sale, the director now owns 4,988 shares in the company, valued at approximately $256,582.72. The disclosure for this sale can be found here. Insiders sold a total of 88,884 shares of company stock worth $4,693,683 in the last quarter. Corporate insiders own 1.40% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new stake in shares of Repligen in the 2nd quarter valued at about $135,000. Seven Eight Capital LP bought a new stake in shares of Repligen in the 3rd quarter valued at about $217,000. Smith Asset Management Group LP grew its position in shares of Repligen by 1,511.8% in the 2nd quarter. Smith Asset Management Group LP now owns 4,658 shares of the biotechnology company’s stock valued at $219,000 after buying an additional 4,369 shares during the last quarter. Benin Management CORP bought a new stake in shares of Repligen in the 2nd quarter valued at about $235,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Repligen in the 2nd quarter valued at about $250,000. Hedge funds and other institutional investors own 92.41% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Article: Why is the conference call important?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply